DORIBAX

Doribax Adverse Events Reported to the FDA Over Time

How are Doribax adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Doribax, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Doribax is flagged as the suspect drug causing the adverse event.

Most Common Doribax Adverse Events Reported to the FDA

What are the most common Doribax adverse events reported to the FDA?

Convulsion	36 (6.23%)
Hepatic Function Abnormal	16 (2.77%)
Renal Impairment	16 (2.77%)
Death	14 (2.42%)
Blood Bilirubin Increased	13 (2.25%)
Blood Creatinine Increased	13 (2.25%)
Off Label Use	13 (2.25%)
Pneumonia	13 (2.25%)
Bradycardia	10 (1.73%)
Interstitial Lung Disease	10 (1.73%)
Oxygen Saturation Decreased	10 (1.73%)
	Show More
Pyrexia	10 (1.73%)
Grand Mal Convulsion	9 (1.56%)
Platelet Count Decreased	9 (1.56%)
Sepsis	9 (1.56%)
Blood Urea Increased	8 (1.38%)
Drug Ineffective	8 (1.38%)
Peritonitis	8 (1.38%)
Renal Failure	8 (1.38%)
White Blood Cell Count Increased	8 (1.38%)
Alanine Aminotransferase Increased	7 (1.21%)
Anuria	7 (1.21%)
Aspartate Aminotransferase Increase...	7 (1.21%)
Leukoencephalopathy	7 (1.21%)
Pseudomonas Infection	7 (1.21%)
Rash	7 (1.21%)
Superinfection	7 (1.21%)
Headache	6 (1.04%)
Septic Shock	6 (1.04%)
Vomiting	6 (1.04%)
Blood Pressure Increased	5 (.87%)
Encephalopathy	5 (.87%)
Gastroenteritis Staphylococcal	5 (.87%)
Hypovolaemic Shock	5 (.87%)
Liver Disorder	5 (.87%)
Overdose	5 (.87%)
Shock	5 (.87%)
Agranulocytosis	4 (.69%)
Altered State Of Consciousness	4 (.69%)
Arrhythmia	4 (.69%)
Arthralgia	4 (.69%)
Arthropathy	4 (.69%)
Blood Pressure Decreased	4 (.69%)
Cholecystitis	4 (.69%)
Cough	4 (.69%)
Drug Rash With Eosinophilia And Sys...	4 (.69%)
Fungal Sepsis	4 (.69%)
Hepatitis Fulminant	4 (.69%)
Leukopenia	4 (.69%)
Lung Abscess	4 (.69%)
Oropharyngeal Pain	4 (.69%)
Pancytopenia	4 (.69%)
Pneumonia Staphylococcal	4 (.69%)
Product Quality Issue	4 (.69%)
Acute Generalised Exanthematous Pus...	3 (.52%)
Bronchospasm	3 (.52%)
Cardiac Arrest	3 (.52%)
Chills	3 (.52%)
Dyspnoea	3 (.52%)
Epilepsy	3 (.52%)
Heart Rate Increased	3 (.52%)
Laboratory Test Abnormal	3 (.52%)
Lower Respiratory Tract Infection	3 (.52%)
Post Procedural Haemorrhage	3 (.52%)
Prothrombin Time Prolonged	3 (.52%)
Pulmonary Sepsis	3 (.52%)
Respiratory Failure	3 (.52%)
Upper Gastrointestinal Haemorrhage	3 (.52%)
Acinetobacter Infection	2 (.35%)
Acute Coronary Syndrome	2 (.35%)
Arterial Rupture	2 (.35%)
Arthritis Infective	2 (.35%)
Bacteraemia	2 (.35%)
Blood Alkaline Phosphatase Increase...	2 (.35%)
Blood Creatinine Decreased	2 (.35%)
Bronchopulmonary Aspergillosis	2 (.35%)
C-reactive Protein Increased	2 (.35%)
Cardiomyopathy	2 (.35%)
Colonic Fistula	2 (.35%)
Confusional State	2 (.35%)
Drug Resistance	2 (.35%)
Dysarthria	2 (.35%)
Gastric Cancer	2 (.35%)
Hallucination	2 (.35%)
Hypersensitivity	2 (.35%)
Hyponatraemia	2 (.35%)
Ileus Paralytic	2 (.35%)
Incorrect Dose Administered	2 (.35%)
Infection	2 (.35%)
Leukaemia	2 (.35%)
Loss Of Consciousness	2 (.35%)
Multi-organ Failure	2 (.35%)
Myocardial Infarction	2 (.35%)
Pancreatitis Acute	2 (.35%)
Pneumonia Bacterial	2 (.35%)
Pulmonary Haemorrhage	2 (.35%)
Systemic Candida	2 (.35%)
Tachypnoea	2 (.35%)
Thrombocytopenia	2 (.35%)
Ventricular Tachycardia	2 (.35%)
Acute Pulmonary Oedema	1 (.17%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Doribax, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Doribax is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Doribax

What are the most common Doribax adverse events reported to the FDA?

Infections - Pathogen Unspecified	59 (10.21%)
Seizures	48 (8.3%)
Renal Disorders	31 (5.36%)
Hepatobiliary	27 (4.67%)
Hepatic And Hepatobiliary	25 (4.33%)
Renal And Urinary Tract Investigati...	24 (4.15%)
Bacterial Infectious	23 (3.98%)
Hematology Investigations	22 (3.81%)
Cardiac Arrhythmias	21 (3.63%)
Epidermal And Dermal Conditions	20 (3.46%)
Respiratory	19 (3.29%)
	Show More
Fatal Outcomes	14 (2.42%)
Cardiac And Vascular Investigations	13 (2.25%)
Encephalopathies	13 (2.25%)
Lower Respiratory Tract Disorders	13 (2.25%)
Therapeutic Procedures And Supporti...	13 (2.25%)
Neurological	12 (2.08%)
Therapeutic And Nontherapeutic Effe...	11 (1.9%)
Body Temperature Conditions	10 (1.73%)
Decreased And Nonspecific Blood Pre...	10 (1.73%)
Metabolic, Nutritional And Blood Ga...	10 (1.73%)
Joint	8 (1.38%)
Medication Errors	8 (1.38%)
Peritoneal And Retroperitoneal Cond...	8 (1.38%)
White Blood Cell	8 (1.38%)
Gastrointestinal Signs	6 (1.04%)
Headaches	6 (1.04%)
Anemias Nonhemolytic And Marrow Dep...	4 (.69%)
Coronary Artery	4 (.69%)
Fungal Infectious	4 (.69%)
Gallbladder	4 (.69%)
Product Quality Issues	4 (.69%)
Allergic Conditions	3 (.52%)
Bronchial Disorders	3 (.52%)
Central Nervous System Vascular	3 (.52%)
Electrolyte And Fluid Balance Condi...	3 (.52%)
Enzyme	3 (.52%)
Gastrointestinal Hemorrhages	3 (.52%)
Investigations, Imaging And Histopa...	3 (.52%)
Myocardial	3 (.52%)
Procedural And Device Related Injur...	3 (.52%)
Deliria	2 (.35%)
Disturbances In Thinking	2 (.35%)
Exocrine Pancreas Conditions	2 (.35%)
Gastrointestinal Conditions	2 (.35%)
Gastrointestinal Motility And Defec...	2 (.35%)
Gastrointestinal Neoplasms Malignan...	2 (.35%)
Leukemias	2 (.35%)
Mental Impairment	2 (.35%)
Platelet	2 (.35%)
Protein And Chemistry Analyses	2 (.35%)
Urinary Tract Signs	2 (.35%)
Vascular Injuries	2 (.35%)
Administration Site Reactions	1 (.17%)
Anxiety Disorders	1 (.17%)
Bone, Calcium, Magnesium And Phosph...	1 (.17%)
Coagulopathies And Bleeding Diathes...	1 (.17%)
Depressed Mood Disorders	1 (.17%)
Gastrointestinal Stenosis And Obstr...	1 (.17%)
Gastrointestinal Ulceration And Per...	1 (.17%)
Heart Failures	1 (.17%)
Hematological And Lymphoid Tissue T...	1 (.17%)
Lipid Analyses	1 (.17%)
Microbiology And Serology	1 (.17%)
Muscle	1 (.17%)
Nephropathies	1 (.17%)
Nervous System, Skull And Spine The...	1 (.17%)
Personality Disorders	1 (.17%)
Physical Examination Topics	1 (.17%)
Pleural	1 (.17%)
Pulmonary Vascular	1 (.17%)
Rickettsial Infectious	1 (.17%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Doribax, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Doribax is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.